NEW YORK, March 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of BioAge Labs, Inc. (NASDAQ: BIOA).Shareholders who purchased shares of BIOA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/bioage-labs-inc-loss-submission-form/?id=134581&from=4CLASS PERIOD: This lawsuit is on ...

Group 1 - The Schall Law Firm has filed a class action lawsuit against BioAge Labs, Inc. for violations of federal securities laws related to its IPO on September 26, 2024 [1] - The lawsuit claims that BioAge made false and misleading statements regarding its lead trial candidate, azelaprag, particularly concerning its safety and potential in obesity therapy [4] - The discontinuation of the STRIDES Phase 2 trial due to safety concerns was contrary to the claims made during the IPO, leading to investor damages when the truth was revealed [4] Group 2 - Investors who purchased BioAge's securities during the IPO are encouraged to contact the Schall Law Firm to discuss their rights [2] - The class in this case has not yet been certified, meaning potential class members are not yet represented by an attorney [3] - The Schall Law Firm specializes in securities class action lawsuits and represents investors globally [5]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased BioAge Labs, Inc. stock during its IPO on September 26, 2024, of the March 10, 2025 deadline to become lead plaintiffs in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased BioAge stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court by March 10, 2025, to serve as lead plaintiff [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Background - The lawsuit alleges that BioAge misrepresented the safety and efficacy of its lead product candidate, azelaprag, in connection with the STRIDES clinical trial, which was expected to yield topline results in 2025 [5]. - BioAge discontinued the STRIDES Phase 2 study after subjects exhibited elevated liver enzyme levels, indicating potential organ damage, which was not disclosed in prior trials [6].

Core Viewpoint - A securities class action lawsuit has been filed against BioAge Labs, Inc. for alleged misleading statements related to its IPO and clinical trials [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased BioAge stock during the IPO on September 26, 2024, with a lead plaintiff deadline set for March 10, 2025 [1]. - Allegations include that BioAge's registration statement and prospectus contained false or misleading statements regarding the STRIDES Phase 2 trial for azelaprag, specifically concerning liver transaminitis and safety concerns [2]. Group 2: Lead Plaintiff Process - Investors can seek to be appointed as a lead plaintiff representative by March 10, 2025, or remain absent class members [3]. - The lead plaintiff will represent the interests of all class members and select counsel for the litigation [3]. Group 3: Law Firm Background - Kessler Topaz Meltzer & Check, LLP has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4].

Core Viewpoint - BioAge Labs, Inc. is facing a class action lawsuit due to alleged violations of the Securities Act of 1933 related to its IPO, with claims that the offering documents were misleading regarding safety concerns and clinical trial expectations [1][3]. Group 1: Class Action Lawsuit Details - The class action lawsuit, titled Soto v. BioAge Labs, Inc., allows purchasers of BioAge Labs stock from its IPO on September 26, 2024, to seek lead plaintiff status by March 10, 2025 [1][5]. - BioAge Labs sold 12.65 million shares at $18.00 per share during its IPO [2]. - The lawsuit alleges that the IPO documents falsely indicated no safety concerns and optimistic expectations for the STRIDES clinical trial [3]. Group 2: Impact of Clinical Trial Results - On December 6, 2024, BioAge Labs announced the discontinuation of the STRIDES Phase 2 study due to liver transaminitis observed in subjects, leading to a stock price drop of over 76% [4]. - By the time the class action lawsuit commenced, BioAge Labs stock was trading around $5.82 per share, significantly lower than the IPO price of $18.00 [4]. Group 3: Legal Representation - Robbins Geller Rudman & Dowd LLP is representing investors in this class action lawsuit and has a strong track record in securities fraud cases, having recovered $6.6 billion for investors in related cases [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased BioAge Labs, Inc. stock during its IPO on September 26, 2024, of the March 10, 2025, deadline to become a lead plaintiff in a class action lawsuit related to the company's alleged misleading statements regarding its clinical trials [1]. Group 1: Class Action Details - Investors who purchased BioAge stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm for more information [3][7]. - A class action lawsuit has already been filed, and interested parties must act by March 10, 2025, to serve as lead plaintiff [3]. Group 2: Background of the Case - The lawsuit claims that BioAge misrepresented the safety and efficacy of its lead product candidate, azelaprag, in connection with the STRIDES clinical trial, which was expected to yield topline results in 2025 [5]. - BioAge's collaboration with Eli Lilly's Chorus clinical development organization was highlighted as part of the trial's design and execution [5]. - The IPO suggested no safety concerns, but the company later discontinued the STRIDES Phase 2 study due to elevated liver enzyme levels in subjects, indicating potential organ damage [6]. Group 3: Allegations of Misleading Information - The lawsuit alleges that BioAge failed to disclose the potential for liver transaminitis from previous clinical trials and preclinical studies, making their statements in the registration statement materially misleading at the time of the IPO [6]. - When the true details about the safety concerns became public, investors reportedly suffered damages [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against BioAge Labs, Inc. due to alleged violations of federal securities laws related to misleading information about its STRIDES Phase 2 clinical trial [2][4]. Group 1: Company Overview - BioAge Labs, Inc. (NASDAQ: BIOA) completed its initial public offering on September 27, 2024, selling 12.65 million shares at $18 per share, including an additional 1.65 million shares purchased by underwriters [4]. - The company faced significant stock price decline following the announcement on December 6, 2024, that it would discontinue the STRIDES Phase 2 study of its drug candidate azelaprag due to liver transaminitis observed in subjects [5][6]. Group 2: Legal Proceedings - A federal securities class action has been filed against BioAge, with a deadline of March 10, 2025, for investors to seek the role of lead plaintiff [2]. - The lead plaintiff is defined as the investor with the largest financial interest who directs and oversees the litigation on behalf of the class [7]. Group 3: Investor Communication - Faruqi & Faruqi encourages investors who suffered losses in BioAge to contact them directly to discuss legal options [1][8]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding BioAge's conduct [8].

Core Viewpoint - BioAge Labs, Inc. is facing a class action lawsuit following the discontinuation of its STRIDES Phase 2 trial for azelaprag due to safety concerns, which led to a significant drop in its stock price [2]. Group 1: Lawsuit Details - The lawsuit is on behalf of shareholders who purchased BioAge stock during the class period related to its IPO on September 26, 2024 [1]. - The discontinuation of the STRIDES Phase 2 trial was announced on December 6, 2024, due to elevated liver transaminase levels, causing the stock price to plummet from $20.09 to $4.65 within a day [2]. Group 2: Shareholder Actions - Shareholders are encouraged to register for the class action by March 10, 2025, to potentially become lead plaintiffs [3]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4].

Core Viewpoint - The Therapeutic Goods Administration (TGA) of Australia has declined the approval of lecanemab for early Alzheimer's disease, which is a setback for patients and healthcare professionals in Australia [1][3]. Company Summary - BioArctic AB, in collaboration with Eisai, developed lecanemab, which is a humanized monoclonal antibody targeting amyloid-beta (Aβ) aggregates [9][14]. - BioArctic has the right to commercialize lecanemab in the Nordic region and is preparing for joint commercialization with Eisai [7][13]. - The company has no development costs for lecanemab and is entitled to payments related to regulatory approvals and sales milestones [13][14]. Industry Summary - Alzheimer's disease (AD) is the most common cause of dementia, accounting for 60-70% of cases, with a significant unmet need for effective treatments [4]. - The number of people living with dementia in Australia is projected to increase from approximately 411,000 in 2023 to about 849,000 by 2058 [4]. - Lecanemab has been approved in 11 markets, including the U.S., Japan, and the UK, and is based on positive Phase 3 clinical trial results [6][10].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased BioAge Labs, Inc. stock during its IPO on September 26, 2024, about the March 10, 2025, deadline to become a lead plaintiff in a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who bought BioAge stock may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must act by March 10, 2025, to serve as lead plaintiff [3][8]. Group 2: Background of the Case - The lawsuit claims that BioAge misrepresented the safety and efficacy of its lead product candidate, azelaprag, in relation to the STRIDES clinical trial, which was expected to yield topline results in 2025 [5]. - BioAge's collaboration with Eli Lilly's Chorus clinical development organization was highlighted, suggesting a robust trial design and execution [5]. - The company discontinued the STRIDES Phase 2 study after subjects exhibited elevated liver enzyme levels, indicating potential organ damage, which was not disclosed in prior trials [6]. Group 3: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, noting its own history of successful settlements [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].